On Litigation Funding: The Drug and Device Industry

"Drug and device cases are particularly
attractive to litigation funders for several
reasons: the cases are highly visible, easy
to spot, and are relatively easy to collect
en masse. The rise of third-party litigation
funding, the grey area in which it currently
operates, and the growth of it in product
liability cases combine to create very real
risks to drug and device manufacturers. "laddon, reilly and angelino, in-house quarterly